MEDLINE INC

Medline Inc. reports a half‑year 2026 rebound: net sales grow, operating income rises, and cash flow strengthens, underscoring robust profitability and strategic growth prospects in medical‑surgical products.

Medline Inc expands global reach with SteraMist®—new EU marketing deals, defense‑sector partnerships, and 99.99% microbial kill verified in field trials.

Medline Inc. Q1 2026: $2.45B revenue, $325M operating income, and strong oncology/immunology pipeline with Phase 3 and regulatory milestones, driving future growth.